PMID- 29113384
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220728
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 46
DP  - 2017 Oct 6
TI  - Subclinical involvement of the liver is associated with prognosis in treatment 
      naive cancer patients.
PG  - 81250-81260
LID - 10.18632/oncotarget.17131 [doi]
AB  - BACKGROUND: Routinely tested liver biomarkers as alanine aminotransferase (ALT), 
      aspartate aminotransferase (AST), gamma-glutamyltransferase (GGT), 
      butyryl-cholinesterase (BChE), albumin and bilirubin are altered in distinct 
      malignancies and hepatic metastases. This study aimed to investigate whether all 
      liver parameters have the ability to predict long-term mortality in treatment 
      naive cancer patients but without a malignant hepatic involvement. METHODS: We 
      prospectively enrolled 555 consecutive patients with primary diagnosis of cancer 
      without prior anticancer therapy. BChE, albumin, AST, ALT, GGT and bilirubin as 
      well as the inflammatory makers C-reactive protein (CRP), serum amyloid A (SAA) 
      and interleukin-6 (IL-6) were determined. All-cause mortality was defined as 
      primary endpoint. RESULTS: During a median follow-up of 25 (IQR16-31) months 186 
      (34%) patients died. All liver parameters were significantly associated with 
      all-cause mortality (p < 0.001 for all). However, for patients without a 
      malignant primary or secondary hepatic involvement (82%) only the functional 
      parameters BChE and albumin remained significantly associated with the primary 
      endpoint (crude HR per 1-IQR increase 0.61, 95%CI:0.49-0.77; p < 0.001 for BChE 
      and 0.58, 95%CI:0.47-0.70; p < 0.001 for albumin). This e ect was persistent 
      after multivariate adjustment (adj.HR per 1-IQR increase 0.65, 95%CI:0.50-0.86; p 
      = 0.002 for BChE and 0.63, 95%CI:0.50-0.79; p < 0.001 for albumin). BChE and 
      albumin correlated inversely with CRP (r = -0.21, p < 0.001 and r = -0.36, p < 
      0.001), SAA (r = -0.19, p < 0.001 and r = -0.33, p < 0.001) and IL-6 (r = -0.13, 
      p = 0.009 and r = -0.17, p = 0.001). CONCLUSIONS: Decreased serum BChE and 
      albumin levels are associated with increased all-cause mortality in 
      treatment-naive cancer patients without a manifest malignant hepatic involvement 
      irrespective of tumor entity or stage. This association may reflect progressing 
      systemic inflammation and metabolic derangement with subclinical involvement of 
      the liver.
FAU - Pavo, Noemi
AU  - Pavo N
AD  - Department of Internal Medicine II, Division of Cardiology, Medical University of 
      Vienna, Vienna, Austria.
FAU - Raderer, Markus
AU  - Raderer M
AD  - Department of Internal Medicine I, Division of Oncology and Hematology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Goliasch, Georg
AU  - Goliasch G
AD  - Department of Internal Medicine II, Division of Cardiology, Medical University of 
      Vienna, Vienna, Austria.
FAU - Wurm, Raphael
AU  - Wurm R
AD  - Department of Internal Medicine II, Division of Cardiology, Medical University of 
      Vienna, Vienna, Austria.
FAU - Strunk, Guido
AU  - Strunk G
AD  - Complexity Research, Vienna, Austria.
FAU - Cho, Anna
AU  - Cho A
AD  - Department of Internal Medicine II, Division of Cardiology, Medical University of 
      Vienna, Vienna, Austria.
FAU - Novak, Johannes F
AU  - Novak JF
AD  - Department of Internal Medicine II, Division of Cardiology, Medical University of 
      Vienna, Vienna, Austria.
FAU - Gisslinger, Heinz
AU  - Gisslinger H
AD  - Department of Internal Medicine I, Division of Oncology and Hematology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Steger, Gunther G
AU  - Steger GG
AD  - Department of Internal Medicine I, Division of Oncology and Hematology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Hejna, Michael
AU  - Hejna M
AD  - Department of Internal Medicine I, Division of Oncology and Hematology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Kostler, Wolfgang
AU  - Kostler W
AD  - Department of Internal Medicine I, Division of Oncology and Hematology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Zochbauer-Muller, Sabine
AU  - Zochbauer-Muller S
AD  - Department of Internal Medicine I, Division of Oncology and Hematology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Marosi, Christine
AU  - Marosi C
AD  - Department of Internal Medicine I, Division of Oncology and Hematology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Kornek, Gabriela
AU  - Kornek G
AD  - Department of Internal Medicine I, Division of Oncology and Hematology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Auerbach, Leo
AU  - Auerbach L
AD  - Department of Gynaecology, Medical University of Vienna, Vienna, Austria.
FAU - Schneider, Sven Thorben
AU  - Schneider ST
AD  - Department of Otorhinolaryngology - Head and Neck Surgery, Medical University of 
      Vienna, Vienna, Austria.
FAU - Parschalk, Bernhard
AU  - Parschalk B
AD  - Department of Otorhinolaryngology - Head and Neck Surgery, Medical University of 
      Vienna, Vienna, Austria.
FAU - Scheithauer, Werner
AU  - Scheithauer W
AD  - Department of Internal Medicine I, Division of Oncology and Hematology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Pirker, Robert
AU  - Pirker R
AD  - Department of Internal Medicine I, Division of Oncology and Hematology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Kiesewetter, Barbara
AU  - Kiesewetter B
AD  - Department of Internal Medicine I, Division of Oncology and Hematology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Pacher, Richard
AU  - Pacher R
AD  - Department of Internal Medicine II, Division of Cardiology, Medical University of 
      Vienna, Vienna, Austria.
FAU - Zielinski, Christoph
AU  - Zielinski C
AD  - Department of Internal Medicine I, Division of Oncology and Hematology, Medical 
      University of Vienna, Vienna, Austria.
FAU - Hulsmann, Martin
AU  - Hulsmann M
AD  - Department of Internal Medicine II, Division of Cardiology, Medical University of 
      Vienna, Vienna, Austria.
LA  - eng
PT  - Journal Article
DEP - 20170416
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5655279
OTO - NOTNLM
OT  - biomarker
OT  - cancer
OT  - inflammation
OT  - liver
OT  - prognosis
COIS- CONFLICTS OF INTEREST The authors have nothing to disclose.
EDAT- 2017/11/09 06:00
MHDA- 2017/11/09 06:01
PMCR- 2017/10/06
CRDT- 2017/11/09 06:00
PHST- 2016/12/29 00:00 [received]
PHST- 2017/04/04 00:00 [accepted]
PHST- 2017/11/09 06:00 [entrez]
PHST- 2017/11/09 06:00 [pubmed]
PHST- 2017/11/09 06:01 [medline]
PHST- 2017/10/06 00:00 [pmc-release]
AID - 17131 [pii]
AID - 10.18632/oncotarget.17131 [doi]
PST - epublish
SO  - Oncotarget. 2017 Apr 16;8(46):81250-81260. doi: 10.18632/oncotarget.17131. 
      eCollection 2017 Oct 6.